According to a market report by Lucintel, the future of the global metastatic colorectal cancer market looks promising with opportunities in the hospitals, cancer centers, ambulatory surgical centers, and others markets. The global metastatic colorectal cancer market is expected to reach an estimated $12.0 billion by 2030 from $9.0 billion in 2024, at a CAGR of 4.0% from 2024 to 2030. The major drivers for this market are growing advancement in treatment therapies, increasing awareness around early detection of cancer, and rising incidence of colorectal cancer.
A more than 150-page report to understand trends, opportunity and forecast in metastatic colorectal cancer market to metastatic colorectal cancer by treatment (chemotherapy, targeted therapies, immunotherapies, monotherapy & combination therapy, and others), drug class (anti-egfr inhibitors, anti-vegf therapies, anti-her2 therapies, immune checkpoint inhibitors, and others), end use (hospitals, cancer centers, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that, within the treatment category, chemotherapy will remain the largest segment over the forecast period.
Within the end use category, anti-vegf therapies will remain the largest segment.
Download sample by clicking on metastatic colorectal cancer market
In terms of region, North America will remain the largest region over the forecast period.
Amgen, Eli Lilly, Pfizer, Roche Holding AG, Merck Sharp & Dohme, Sanofi, Taiho Oncology, Bristol Myers Squibb, Bayer, Novartis are the major suppliers in the metastatic colorectal cancer market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com To get access of more than 1000 reports at fraction of cost visit Lucintel’s Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact: Roy Almaguer Lucintel Dallas, Texas, USA Email: roy.almaguer@lucintel.com Tel. +1-972-636-5056
Explore Our Latest Publications
System Level Test Market
Smart NIC Market
Serial (SPI) NOR Flash Market
Heavy-Duty Connector Market
IT Connector Market
Needle-Free IV Connector Market Market
RF Coaxial Connector Market
Space Grade Connector Market
Underwater Connector Market
Wire-to-Board Connector Market Market
Media Contact
Company Name: Lucintel
Contact Person: Roy Almaguer
Email: Send Email
Phone: 972.636.5056
Address:8951 Cypress Waters Blvd., Suite 160
City: Dallas
State: TEXAS
Country: United States
Website: https://www.lucintel.com/